Noa Dagan
Noa Dagan, PhD
Former Research Fellow in Biomedical Informatics, Harvard Medical School
Mentor: Isaac Kohane, MD, PhD

Noa Dagan is a public health physician and researcher. She holds an MD and an MPH from the Hebrew University, and a Ph.D. in Computer Science from Ben-Gurion University.

Dagan is the director of data and AI-driven medicine at the Clalit Research Institute – the research institute of Israel's largest healthcare organization, insuring and treating over 50% of the Israeli population. Her responsibilities include the development and implementation of digital healthcare solutions to promote preventive, proactive and personalized medicine. She leads the entire lifecycle of AI-driven interventions, from conception, through machine-learning modeling, to implementation in medical practice.

Dagan's research focuses on practical implementations of machine-learning algorithms using clinical data, with a specific interest in the prevention of cardiovascular events and osteoporotic fractures. Dr. Dagan is also active in research of ethical aspects of machine-learning models such as fairness.

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
Authors: Magen O, Waxman JG, Makov-Assif M, Vered R, Dicker D, Hernán MA, Lipsitch M, Reis BY, Balicer RD, Dagan N.
N Engl J Med
View full abstract on Pubmed
Comparing COVID-19-related hospitalization rates among individuals with infection-induced and vaccine-induced immunity in Israel.
Authors: Waxman JG, Makov-Assif M, Reis BY, Netzer D, Balicer RD, Dagan N, Barda N.
Nat Commun
View full abstract on Pubmed
Validation of Heart Failure-Specific Risk Equations in 1.3 Million Israeli Adults and Usefulness of Combining Ambulatory and Hospitalization Data from a Large Integrated Health Care Organization.
Authors: Khan SS, Barda N, Greenland P, Dagan N, Lloyd-Jones DM, Balicer R, Rasmussen-Torvik LJ.
Am J Cardiol
View full abstract on Pubmed
Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older.
Authors: Auster O, Finkel U, Dagan N, Barda N, Laufer A, Balicer RD, Ben-Shachar S.
JAMA Netw Open
View full abstract on Pubmed
Improving Cardiovascular Disease Prediction Using Automated Coronary Artery Calcium Scoring from Existing Chest CTs.
Authors: Barda N, Dagan N, Stemmer A, Yuval J, Bachmat E, Elnekave E, Balicer R.
J Digit Imaging
View full abstract on Pubmed
Indirect protection of children from SARS-CoV-2 infection through parental vaccination.
Authors: Hayek S, Shaham G, Ben-Shlomo Y, Kepten E, Dagan N, Nevo D, Lipsitch M, Reis BY, Balicer RD, Barda N.
Science
View full abstract on Pubmed
Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting.
Authors: Mittelman M, Magen O, Barda N, Dagan N, Oster HS, Leader A, Balicer R.
Blood
View full abstract on Pubmed
Using population-level incidence of hepatitis C virus and immigration status for data-driven screening policies: a case study in Israel.
Authors: Leventer-Roberts M, Dagan N, Berent JM, Brufman I, Hoshen M, Braun M, Balicer RD, Feldman BS.
J Public Health (Oxf)
View full abstract on Pubmed
The role of observational studies based on secondary data in studying SARS-CoV-2 vaccines.
Authors: Barda N, Dagan N.
Clin Microbiol Infect
View full abstract on Pubmed
Previously undiagnosed cancer in patients with arterial thrombotic events - A population-based cohort study.
Authors: Leader A, Dagan N, Barda N, Goldberg I, Raanani P, Spectre G, Balicer R, Gafter-Gvili A.
J Thromb Haemost
View full abstract on Pubmed